CVRx, Inc. (CVRX)

Market Cap	207.53M
Revenue (ttm)	42.09M
Net Income (ttm)	-52.01M
Shares Out	21.60M
EPS (ttm)	-2.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,059
Open	9.83
Previous Close	9.53
Day's Range	9.46 - 9.88
52-Week Range	6.40 - 33.14
Beta	1.21
Analysts	Buy
Price Target	13.80 (+43.6%)
Earnings Date	Jul 29, 2024

About CVRX

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 an...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 30, 2021
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: CVRX

Financial Performance

In 2023, CVRx, Inc.'s revenue was $39.30 million, an increase of 74.89% compared to the previous year's $22.47 million. Losses were -$41.20 million, -0.55% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price forecast is $13.8, which is an increase of 43.60% from the latest price.

Price Target

$13.8

(43.60% upside)

Analyst Consensus: Buy